Imugene Limited (IUGNF)
USD 0.03
(4.0%)
USD 0.03
(4.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -5.83 Million AUD | -161.0% |
| 2023 | 9.57 Million AUD | -9.36% |
| 2022 | 10.56 Million AUD | 100.46% |
| 2021 | 5.26 Million AUD | 30.06% |
| 2020 | 4.05 Million AUD | -0.31% |
| 2019 | 4.06 Million AUD | 121.1% |
| 2018 | 1.83 Million AUD | 58.14% |
| 2017 | 1.16 Million AUD | -25.64% |
| 2016 | 1.56 Million AUD | 144.74% |
| 2015 | 638.67 Thousand AUD | 18.64% |
| 2014 | 538.31 Thousand AUD | 159.78% |
| 2013 | 207.22 Thousand AUD | -12.16% |
| 2012 | 235.91 Thousand AUD | -89.41% |
| 2011 | 2.22 Million AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | -100.0% |
| 2007 | 374.56 Thousand AUD | 0.0% |
| 2006 | - AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| 2004 | - AUD | -100.0% |
| 2003 | 19.00 AUD | -100.0% |
| 2002 | 1.11 Million AUD | 15754.57% |
| 2001 | 7044.00 AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | -100.0% |
| 1997 | 3.85 Million AUD | 1288.13% |
| 1996 | 278 Thousand AUD | 47.87% |
| 1995 | 188 Thousand AUD | 0.0% |
| 1994 | - AUD | 0.0% |
| 1993 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | - AUD | 0.0% |
| 2024 Q1 | 4.03 Million AUD | 15.85% |
| 2024 Q2 | 4.03 Million AUD | 0.0% |
| 2024 FY | -5.83 Million AUD | -161.0% |
| 2023 Q2 | 2.4 Million AUD | -0.0% |
| 2023 Q3 | 3.48 Million AUD | 44.69% |
| 2023 FY | 9.57 Million AUD | -9.36% |
| 2023 Q4 | 3.48 Million AUD | 0.0% |
| 2023 Q1 | 2.4 Million AUD | -36.87% |
| 2022 Q1 | 2.67 Million AUD | 69.9% |
| 2022 FY | 10.56 Million AUD | 100.46% |
| 2022 Q4 | 3.81 Million AUD | 0.0% |
| 2022 Q3 | 3.81 Million AUD | 42.63% |
| 2022 Q2 | 2.67 Million AUD | 0.0% |
| 2021 Q2 | 2.04 Million AUD | -0.0% |
| 2021 Q1 | 2.04 Million AUD | 132.22% |
| 2021 FY | 5.26 Million AUD | 30.06% |
| 2021 Q4 | 1.57 Million AUD | 0.0% |
| 2021 Q3 | 1.57 Million AUD | -22.98% |
| 2020 Q4 | 879.59 Thousand AUD | 0.0% |
| 2020 FY | 4.05 Million AUD | -0.31% |
| 2020 Q3 | 879.59 Thousand AUD | -25.92% |
| 2020 Q2 | 1.18 Million AUD | 0.0% |
| 2020 Q1 | 1.18 Million AUD | -2.35% |
| 2019 Q1 | 812.65 Thousand AUD | 42.27% |
| 2019 FY | 4.06 Million AUD | 121.1% |
| 2019 Q4 | 1.21 Million AUD | -2.81% |
| 2019 Q3 | 1.25 Million AUD | 53.94% |
| 2019 Q2 | 812.65 Thousand AUD | 0.0% |
| 2018 Q1 | 349.17 Thousand AUD | 76.82% |
| 2018 Q2 | 349.17 Thousand AUD | 0.0% |
| 2018 Q3 | 571.21 Thousand AUD | 63.59% |
| 2018 Q4 | 571.21 Thousand AUD | 0.0% |
| 2018 FY | 1.83 Million AUD | 58.14% |
| 2017 FY | 1.16 Million AUD | -25.64% |
| 2017 Q4 | 197.47 Thousand AUD | 0.0% |
| 2017 Q3 | 197.47 Thousand AUD | -48.65% |
| 2017 Q2 | 384.54 Thousand AUD | -0.0% |
| 2017 Q1 | 384.54 Thousand AUD | -17.12% |
| 2016 Q1 | 318.17 Thousand AUD | 306.16% |
| 2016 Q4 | 463.95 Thousand AUD | 0.0% |
| 2016 Q3 | 463.95 Thousand AUD | 45.82% |
| 2016 Q2 | 318.17 Thousand AUD | 0.0% |
| 2016 FY | 1.56 Million AUD | 144.74% |
| 2015 Q4 | 78.33 Thousand AUD | 0.0% |
| 2015 FY | 638.67 Thousand AUD | 18.64% |
| 2015 Q1 | 241 Thousand AUD | -9.31% |
| 2015 Q2 | 241 Thousand AUD | -0.0% |
| 2015 Q3 | 78.33 Thousand AUD | -67.5% |
| 2014 Q3 | 265.74 Thousand AUD | 7686.17% |
| 2014 Q4 | 265.74 Thousand AUD | 0.0% |
| 2014 Q2 | 3413.00 AUD | -0.03% |
| 2014 Q1 | 3414.00 AUD | -96.45% |
| 2014 FY | 538.31 Thousand AUD | 159.78% |
| 2013 FY | 207.22 Thousand AUD | -12.16% |
| 2013 Q3 | 96.17 Thousand AUD | 0.0% |
| 2013 Q4 | 96.17 Thousand AUD | 0.0% |
| 2012 FY | 235.91 Thousand AUD | -89.41% |
| 2011 FY | 2.22 Million AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | -100.0% |
| 2007 FY | 374.56 Thousand AUD | 0.0% |
| 2006 FY | - AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2004 FY | - AUD | -100.0% |
| 2003 FY | 19.00 AUD | -100.0% |
| 2002 FY | 1.11 Million AUD | 15754.57% |
| 2001 FY | 7044.00 AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | -100.0% |
| 1997 FY | 3.85 Million AUD | 1288.13% |
| 1996 FY | 278 Thousand AUD | 47.87% |
| 1995 FY | 188 Thousand AUD | 0.0% |
| 1994 FY | - AUD | 0.0% |
| 1993 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 7707.833% |
| CSL Limited | 7.56 Billion USD | 100.077% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 138.935% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 188360.767% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 149.888% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 104.903% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -17000.583% |
| Mesoblast Limited | -35.16 Million USD | 83.394% |
| Marizyme, Inc. | 457.7 Thousand USD | 1375.906% |
| Genus plc | 178.7 Million USD | 103.268% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 1523.78% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -52989.536% |
| ContraFect Corporation | -154 Thousand USD | -3692.11% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -11579.698% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -962.29 Thousand USD | -506.865% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -1407.054% |
| MultiCell Technologies, Inc. | 49.32 USD | 11840831.955% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 114.504% |
| EV Biologics, Inc. | 48.9 Thousand USD | 12042.431% |
| Q BioMed Inc. | -8988.00 USD | -64873.843% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 120.668% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -37762.092% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 8442.641% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -4600.042% |
| SQZ Biotechnologies Company | 9.79 Million USD | 159.627% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -117829.099% |
| Arch Therapeutics, Inc. | -2439.00 USD | -239336.203% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 8984.873% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 4256.476% |
| Neon Bloom, Inc. | - USD | Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 102.653% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 9484.902% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -5888.667% |
| GB Sciences, Inc. | -624.00 USD | -935773.237% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -6688.312% |
| argenx SE | 1.1 Billion USD | 100.527% |
| HST Global, Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -2807519.712% |
| Enzolytics Inc. | 30.7 Thousand USD | 19117.354% |
| Resverlogix Corp. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 1310.499% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 77.363% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 113.165% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -411.562% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -1035.031% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 1045.902% |
| ONE Bio Corp. | 20.12 Million USD | 129.017% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 101.426% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -65842.288% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -6864.721% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -826.757% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 691.089% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 160.762% |
| BioStem Technologies, Inc. | 15.42 Million USD | 137.86% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -49243.887% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -12001.057% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 3407.572% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 3407.572% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 530.305% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -20037.41% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 1397.62% |
| SYBLEU INC | 11.69 Thousand USD | 50030.31% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -1727.769% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 226.733% |
| Bioxytran, Inc. | -8285.00 USD | -70387.013% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -1465.643% |
| Neutra Corp. | 14.33 Thousand USD | 40838.396% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -7021.767% |
| PureTech Health plc | -1.6 Million USD | -264.307% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -483.264% |
| IXICO plc | 3.27 Million USD | 278.589% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -741.477% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -226.066% |
| CSL Limited | 7.7 Billion USD | 100.076% |
| Cellectis S.A. | 18 Thousand USD | 32543.606% |